雖然這篇Finerenone mechanism鄉民發文沒有被收入到精華區:在Finerenone mechanism這個話題中,我們另外找到其它相關的精選爆讚文章
[爆卦]Finerenone mechanism是什麼?優點缺點精華區懶人包
你可能也想看看
搜尋相關網站
-
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#1Mineralocorticoid Receptor Antagonists: a Comprehensive ...
Purpose of review: We aim to review the mechanism of action and safety profile ... More specifically, finerenone is a new medication that is ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#2Finerenone: Uses, Interactions, Mechanism of Action - DrugBank
Finerenone is a non-steroidal selective mineralocorticoid receptor (MR) antagonist with no significant affinity or activity at androgen, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#3the role of finerenone | Nephrology Dialysis Transplantation
THE MECHANISM OF ACTION OF FINERENONE. The MR belongs to the superfamily of nuclear hormone receptors and is ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#4Finerenone - Wikipedia
Finerenone acts as an antagonist to mineralocorticoid receptors harboring the S810L mutation, unlike other traditional MR inhibitors such as spironolactone and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#5Finerenone - an overview | ScienceDirect Topics
New Treatments for Diabetic Kidney Disease Targeting Intrinsic Kidney Mechanisms. Several promising therapies have been evaluated in clinical trials, including ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#6Effect of Finerenone on Chronic Kidney Disease Outcomes in ...
Preclinical data showed that the kidney and cardiovascular benefits of finerenone were associated with potent antiinflammatory and antifibrotic ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#7Finerenone and Cardiovascular Outcomes in ... - AHA Journals
In FIDELIO-DKD, changes in blood pressure were modest and similar between groups, suggesting a largely nonhemodynamic mechanism of action of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#8Treatment of diabetic kidney disease - UpToDate
由 V Perkovic 著作 — Finerenone reduces the progression of kidney function impairment and ... A range of additional mechanisms may explain the benefits of SGLT2 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#9Finerenone: A Potential Treatment for Patients with Chronic ...
Regarding haemodynamic changes associated with finerenone, ... the treatment of cardiorenal diseases by different mechanisms.26 Similarly, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#10Finerenone in Predominantly Advanced CKD and Type 2 ...
Introduction: FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease ... because of their different mechanisms of action. Data.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#11Kerendia (finerenone) | CenterWatch
Mechanism of Action ... Kerendia (finerenone) is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR), which is activated by aldosterone ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#12Mineralcorticoid receptor blockers in chronic kidney disease
There are several mechanisms involved in the genesis of renal interstitial fibrosis and ... In the model of AKI due to ischemia-reperfusion, finerenone, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#13Finerenone Reduces New-Onset Atrial Fibrillation in Patients ...
Patients with CKD and T2D were randomized (1:1) to finerenone or placebo. ... A potential mechanism explaining the benefit of finerenone on ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#14Expanding the therapy options for diabetic kidney disease
Finerenone treatment reduced the primary ... kidney protection provided by finerenone ... mechanisms beyond albuminuria regression3.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#15Finerenone Impedes Aldosterone-dependent Nuclear Import ...
Here, we characterized the molecular mechanisms of action of finerenone and spironolactone at several key steps of the MR signaling pathway.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#16Hyperkalemia with Mineralocorticoid Receptor Antagonist Use ...
With the recent publication of the Finerenone in Reducing Kidney Failure and ... We propose that the operative mechanism of action blocking ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#17Mineralocorticoid Receptor Antagonists in Diabetic Kidney ...
Recently, nonsteroidal MRAs, including finerenone, have been developed. ... aldosterone-independent mechanism (Frimodt-Moller et al., 2020).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#18Kerendia (finerenone) dosing, indications, interactions ...
Medscape - Chronic kidney disease dosing for Kerendia (finerenone), frequency-based adverse effects, ... and finerenone. No Results ... Mechanism of Action.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#19Direct Blood Pressure-Independent Anti-Fibrotic Effects by the ...
Here, we investigated potential direct anti-fibrotic effects and mechanisms of nonsteroidal MR antagonism by finerenone or SGLT2 inhibition by empagliflozin ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#20Nonsteroidal antagonists of the mineralocorticoid receptor
In contrast, data from two clinical phase II trials are available for finerenone (Bayer) which demonstrated safety and efficacy in patients with heart ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#21Finerenone: a New Mineralocorticoid Receptor Antagonist ...
The mechanism of action of finerenone is different than previous "similar" drugs. ... ... Although classic mineralocorticoid receptor antagonists bind in ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#22Efficacy and safety of finerenone in patients with chronic ...
Efficacy and safety of finerenone in patients with chronic kidney disease: a systematic ... This may be associated with the treatment mechanism of MRAs.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#23New Mineralocorticoid Receptor Antagonist for Heart Failure
... finerenone provides greater cardiac protection and has different binding to the receptor than eplerenone and this could be the mechanism ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#24Mineralocorticoid Receptor Antagonists in Diabetic Kidney ...
Finerenone 5–10 mg/day was at least as effective as spironolactone 25 mg or 50 mg/day in ... through an anti-inflammatory mechanism in type 2 diabetic rats.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#25Finerenone (Kerendia®) - Straight Healthcare
Finerenone blocks aldosterone receptors in the collecting duct. It also blocks mineralocorticoid receptors in nonepithelial tissues (e.g. heart, blood vessels).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#26Efficacy and safety of finerenone in patients with chronic ...
GLP-1 receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms. Front Pharmacol. 2020;11:967. 4. Yin WL, Bain SC, Min T. The effect of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#27A randomized controlled study of finerenone vs. eplerenone in ...
There are mechanisms that may explain the decrease in the clinical composite endpoint in the finerenone (1020 mg) group. Finerenone has a unique pharmacodynamic ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#28and 20-mg tablets | Mechanisms - KERENDIA® (finerenone) 10
Mineralocorticoid receptor is1: Activated by aldosterone and cortisol. Overactivation of the mineralocorticoid receptor is1: Thought to contribute to ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#29Finerenone: MedlinePlus Drug Information
Finerenone is in a class of medications called mineralocorticoid receptor (MR) antagonists. It works by blocking the activity of certain ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#30215341Orig1s000 - Accessdata.fda.gov
Selective mineralocorticoid receptor (MR) antagonist. Proposed Mechanism of action. Finerenone has a high potency and selectivity for the MR.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#31Berlin, September 20, 2021 – Bayer announced today the ...
... new treatments that can target kidney-specific disease mechanisms are ... Finerenone has already demonstrated benefits on kidney and cardiovascular ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#32Finerenone and Cardiorenal Outcomes in Type 2 Diabetes ...
FIDELIO-DKD also showed a greater absolute benefit of finerenone on composite kidney outcome in patients with CVD. The underlying mechanism of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#33Kerendia (Finerenone Tablets): Uses, Dosage, Side ... - RxList
Mechanism Of Action ... Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR), which is activated by ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#34Finerenone - Cigna
Finerenone (Kerendia) is considered medically necessary when the ... Based on their mechanism of action, an increase in adverse events.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#35Finerenone Reduces Intrinsic Arterial Stiffness in Munich ...
ilar pathophysiologic mechanisms as a common pathway linking the cardiovascular-renal axis in patients with al- buminuria [22–25].
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#36ClinicalThought - CKD in T2D: FAQs 1 - Clinical Care Options
Finerenone also has other benefits in terms of tolerability and its mechanism of action that spironolactone does not have, and you don't ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#371546.full.pdf - Drug Metabolism & Disposition
Mass balance and biotransformation of finerenone, a nonsteroidal ... transit time, which may be the underlying mechanism; the basis of this.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#38Non-steroidal MRAs for Chronic Kidney Disease - American ...
What to know in terms of the mechanism of action of non-steroidal MRA finerenone compared with other therapies used to treat patients with ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#39The Ascent of Mineralocorticoid Receptor Antagonists in ...
Presently mineralocorticoid receptor antagonists such as spironolactone, eplerenone and finerenone are being investigated as both monotherapies and as ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#40Finerenone – are we there yet with a non-steroidal ...
The non-steroidal mineralocorticoid receptor antagonist finerenone protects ... Although finerenone has a different mechanism of action to these medicines ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#41Cardiovascular Outcomes With Finerenone in Patients With ...
Finerenone has several potential mechanisms by which it may be preventing atrial fibrillation, not only because it controls blood pressure, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#42finerenone (Kerendia™) - EOCCO.com
Finerenone (Kerendia) is a selective, nonsteroidal mineralocorticoid receptor antagonist (MRA) ... T2D via hemodynamic and metabolic mechanisms.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#43Presentation title goes here - Clinical Trial Results
Effect of finerenone on cardiovascular outcomes in patients with chronic ... Finerenone has a unique binding mechanism and distribution vs ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#44National Institute for Health and Care Excellence - NICE
Finerenone for treating chronic kidney disease in people with type 2 diabetes ... which supports a different mechanism of action for finerenone (3).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#45Finerenone | Clinical Diabetes
Finerenone is a selective mineralocorticoid receptor (MR) antagonist being studied for its potential in reducing cardiovascular and renal adverse outcomes ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#46Finerenone and Cardiovascular Outcomes in ... - ReachMD
mineralocorticoid receptor antagonist finerenone on kidney and ... mechanisms in this population include increased MR expression, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#47Potential Benefit of Mineralocorticoid Receptor Antagonists in ...
However, a selectivity mechanism allows aldosterone to preferentially ... using the nonsteroidal MRA finerenone has similar effects, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#48Kidney Week - American Society of Nephrology
... Receptor Antagonist Finerenone and the SGLT2 Inhibitor Empagliflozin in a Non-Diabetic Cardiorenal Rat Model. Session Information. CKD Mechanisms - 2
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#49Drug Study Offers New Hope to Patients with Both Chronic ...
"We now have evidence that doctors can safely slow diabetic kidney disease progression and reduce cardiovascular event rates using finerenone, a ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#50Finerenone receives positive EMA opinion for treatment of ...
Assuming finerenone receives approval, it is set to add a new (potentially synergistic, given the differing drug mechanisms) treatment ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#51Finerenone in Diabetic Nephropathy - NephJC
finerenone ; fidelio; randomized controlled trial; RCT; NEJM; diabetes; ... Mechanisms of cardiac and Kidney damage induced by Aldosterone ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#52Nephrology
Finerenone in Reducing Kidney Failure and Disease. Progression in Diabetic Kidney ... with a variety of mechanisms have failed to slow CKD.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#53Cardiovascular events with finerenone in kidney disease and ...
Finerenone has proved effective in the treatment of patients with CKD in Phase II studies. The Phase III programme covers two studies: the Finerenone in ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#54FIND-CKD and Next Steps for Finerenone Research With ...
... potential research priorities surrounding finerenone moving forward. ... for a mechanism because in hypertension, especially in obesity, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#55Finerenone: A Non-steroidal Mineralocorticoid Receptor ...
mechanisms evolved by commensal bacteria to render the environment more hostile to certain pathogens [9]. This study.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#56Emerging Nonglucose Mechanisms for CKD in T2D
Mechanism of action (MOA) of emerging treatments for CKD in T2D; Emerging clinical trial ... Finerenone is a novel non-steroidal selective MRA that inhibits ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#57搜索
Here, we investigated potential direct anti-fibrotic effects and mechanisms of nonsteroidal MR antagonism by finerenone or SGLT2 inhibition ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#58Data Show Finerenone May Delay Onset of Atrial Fibrillation ...
Patients with chronic kidney disease and type 2 diabetes (T2D) administered the nodel treatment finerenone were found approximately 30% less ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#59Kerendia (finerenone) - eMPR.com
Mechanism of Action. ▫ Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR), which blocks.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#60ACC.21: Finerenone Shows Potential to Delay Afib Onset in ...
As a possible mechanism behind the effect researchers explained that preclinical studies suggest finerenone may help reduce scarring and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#61FDA Approves KERENDIA to Reduce EGFR Decline in Adults ...
Mechanism of Action (MOA), Pharmacokinetics (PK), and Pharmacodynamics (PD). MOA: Finerenone is a non-steroidal mineralocorticoid receptor ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#62Kerendia Prescribing Information - Bayer
KERENDIA (finerenone) tablets, for oral use ... 12.1 Mechanism of Action ... finerenone exposure [see Clinical Pharmacology (12.3)], which may reduce the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#63The novel mineralocorticoid receptor antagonist finerenone ...
Thus, finerenone appears to provide favorable vascular effects through ... The underlying molecular signaling mechanisms responsible for the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#64The advent of novel nonsteroidal mineralocorticoid receptor ...
Mineralocorticoid receptor antagonists (MRAs) in heart failure 0:00 · Development of new non-steroidal MRAs 1:09 · ODD-trial: comparing finerenone ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#65FDA Approves KERENDIA (Finerenone) to Reduce ... - ASCPT
Mechanism of Action (MOA), Pharmacokinetics (PK), and Pharmacodynamics (PD) MOA: Finerenone is a non-steroidal mineralocorticoid receptor ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#66Bayer Seeks Speedy EMA Review For Diabetic Kidney ...
... Speedy EMA Review For Diabetic Kidney Disease Drug Finerenone ... to the agency's accelerated assessment mechanism are logged in this ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#67Bayer's FIDELIO-DKD Phase III Study Demonstrated ...
Bayer announced today that detailed results from the FIDELIO-DKD Phase III study demonstrated that the investigational drug finerenone ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#68Diabetic Kidney Disease (DKD), CMHC Digital Education Hub
Finerenone is FDA Approved in Patients with Diabetic Kidney Disease. July 9, 2021 – The FDA announced that ... Finerenone - Mechanism of Action. Watch Now ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#69Finerenone reduces CKD progression, CV risk - MIMS Malaysia
... selective mineralocorticoid receptor antagonist finerenone reduced ... of finerenone may partly be mediated by natriuretic mechanisms,” ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#70Finerenone Investor-Webinar - YouTube
0:00 / 56:20•Watch full video. Live. •. Scroll for details. Finerenone Investor-Webinar. 455 views455 views. Streamed live on Nov 15, 2021.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#71Bayer faces an uphill fight with finerenone | Evaluate
Pivotal data on finerenone might see it approved, but competing in the ... point that “mechanisms of action differ between drug classes”.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#72Finerenone: A Novel Approach to Chronic Kidney Disease in ...
As part of its mechanism of action, finerenone has been shown to reduce chronic inflammation and fibrosis (scarring) in the kidney.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#73Kidney meetings. clinical applications and science for all ...
... particularly the most recently approved agent finerenone, should play a “central ... Meeting Objectives Review the mechanisms by which structural racism ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#74Figure 1 from New approaches in the treatment of hypertension.
Mechanism of action of anti-aldosterone agents. ... Mineralocorticoid receptor agonists (MRAs), such as finerenone, compete for the binding ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#75Resonant_Therapy-Molecular_Biology_55 : ok33 - Internet ...
17 Finerenone 15m session - 15:03 ... The most common known mechanism is autonomic neuropathy of the nerve which innervates the stomach: the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#76flipping birds drugs. Shop Valentine's Day Candy & Chocolate
... and if they excrete their gooey defense mechanism, it means the product isn't ... This is a taxpayer-funded show targeted at pre-K children. finerenone.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#77Reduce vasoconstriction reddit - Candure
The diving reflex is a clever physiological mechanism enabling the body to ... Nov 14, 2021 · Of these, finerenone (BAY94-8862) was recently approved to ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#78ACCEL Lite: Takeaways From 2021 In Imaging And ...
ACCEL Lite: RV Pacing Induced Cardiomyopathy: Mechanisms, ... ACCEL Lite: ESC Late Breaker: FIGARO-DKD: Finerenone in Patients With Chronic ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#79Finerenone: third-generation mineralocorticoid receptor ...
Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#80Learn More Acquire & Launch Peak acquires and launches or ...
... contributions from our launch products Nubeqa, Finerenone and Verquvo. ... 1bn) in peak sales driven by its unique mechanism of action targeting the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#81Finerenone Cuts Kidney, Heart Risks in CKD and T2D
In FIDELIO-DKD, we hypothesized that the MR antagonism with finerenone would slow kidney disease progression and reduce cardiovascular ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#82Brenner and Rector's The Kidney E-Book - Google 圖書結果
Table 49.37 New Drugs for Hypertension Drug Mechanism of Action Status BAY-94-8862 (Finerenone) Mineralocorticoid receptor antagonist Phase llb LCI699 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#83Finerenone - Glucocorticoid Receptor - TargetMol
Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist with IC50 of 18 nM for the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#84Kidney Disease in Diabetes - 第 110 頁 - Google 圖書結果
Reduction in albuminuria was demonstrated with Finerenone. 5. ... TREATMENT IMPLICATIONS Appreciation of the mechanisms involved in the initiation.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#85Kidney Protection: A Practical Guide to Preserving Renal ...
There is an ongoing larger Figaro-CKD RCT* investigating finerenone. ... Through these 2 putative mechanisms, these drugs confer both cardiac and renal ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?>
finerenone 在 コバにゃんチャンネル Youtube 的最佳解答
finerenone 在 大象中醫 Youtube 的精選貼文
finerenone 在 大象中醫 Youtube 的精選貼文